Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins approved for clinical use. However, selection of an optimum target and payload c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Hoffmann, Ricarda M., Mele, Silvia, Cheung, Anthony, Larcombe-Young, Daniel, Bucaite, Gintare, Sachouli, Eirini, Zlatareva, Iva, Morad, Hassan O. J., Marlow, Rebecca, McDonnell, James M., Figini, Mariangela, Lacy, Katie E., Tutt, Andrew J. N., Spicer, James F., Thurston, David E., Karagiannis, Sophia N., Crescioli, Silvia
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7264231/
https://ncbi.nlm.nih.gov/pubmed/32483228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-65860-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares